Emerging Paradigms in Delivery Systems for Antitubercular Therapy

Rajeev Sharma is an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Madhya Pradesh, Gwalior, India. He earned his B.Pharm, M.Pharm, and Ph.D. in Pharmaceutical Sciences from Dr. H. S. Gour Central University, Sagar, India. Dr. Sharma has approximately 13 years of experience in both teaching and industry. He has served as a Junior Research Fellow under AICTE, an ICMR-SRF, and a CSIR-RA Fellow during his research career, and has worked as an Assistant Professor in academia and as a Senior Formulation Development Scientist in the R&D industry. Dr. Sharma has edited two international and two national books and has authored over 30 publications and 21 book chapters in international reference books. His work focuses on recent concepts in immunology, nanobiotechnology, novel drug delivery systems, and targeted and controlled drug delivery of bioactives for the treatment of diseases such as cancer and diabetes. He is a life member of the Association of Pharmaceutical Teachers of India (APTI). Dr. Sharma's work has been cited approximately 1,200 times, and he has an h-index of 17. The cumulative impact factor of his published papers is around 120, according to SCOPUS. He is currently working on a research project funded by the Madhya Pradesh Council of Science and Technology (MPCST). Dr. Sharma has received several awards for his research, including the Young Research Scholar award and various awards for best oral and poster presentations at national and international conferences. His current research interest is in nanocarrier-based targeted approaches for the effective delivery of bioactives.Dr. Mishra is working as Professor in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty-two years of teaching and research experience. He has more than 140 publications of International and National repute in recent concepts of novel drug delivery systems, localized drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders. Dr. Mishra more than 4100 citations with h- index 36. The total cumulative Impact Factor of his published papers is more than 300 (as per SCOPUS). He has also written more than 25 Books and 45 book chapters in Elsevier, Bentham, Springer and Wiley Publication etc. He has also been granted 3 international patents and 6 Indian patents. Dr. Mishra is recipient of “Distinguished Professor Award” 2019 from DST-NSTMIS, SPAICS, Indore, and M.P. in September 2019. Dr. Mishra has received the “Distinguished Professor Award '' 2021 from Indian Pharmaceutical Association, MP State Branch, Indore. Dr Mishra has received Best Academician Award in the Indian Pharmacy Graduate Association, M.P. State International Conference held on 06th May 2023 at DAVV Auditorium, Indore, India. He is also received one MPCST Project entitled “Dual functional colon- targeted tofacitinib and probiotics loaded microparticles for the treatment of Inflammatory Bowel Disease (2023-24).Laxmikant Gautam is a PhD Scholar in the Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India. Professor S.P. Vyas works in the Department of Pharmacy, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India.

• 1. Introduction: An Overview of Novel Approaches for the Treatment of Tuberculosis2. Theragnostic Approaches for the Management of Tuberculosis3. Role of Inorganic Nanoparticles for the Treatment of Tuberculosis4. Role of Polymeric Nanoparticles for the Treatment of Tuberculosis5. Role of Vesicular Carriers for the Treatment of Tuberculosis6. Polymeric Micelles in Therapy of Tuberculosis7. Herbal Approaches for the Treatment of Tuberculosis8. Role of Gut-lung axis in Tuberculosis9. Mucoadhesive Drug Delivery System(s) for the Treatment of Tuberculosis10. Current Gene Therapy Approaches for the Treatment of Tuberculosis11. Novel Targets and Drugs for the Treatment of Tuberculosis12. Targeting Inflammation and Oxidative Stress for the Treatment of Tuberculosis13. Potential Approaches for the Treatment of Drug-resistant Tuberculosis14. Targeted Drug Delivery to the Macrophagic Cellular Tropics in Tuberculosis15. Combination Antitubercular Therapy Using Nanomedicine to Treat and Eradicate Tuberculosis16. Tuberculosis Vaccines: Advancements and Ongoing Clinical Trials17. Future Prospects and Regulatory Aspects for the Management of Tuberculosis